Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators

• Published in: Biochemical pharmacology Vol. 51; no. 11; pp. 1553 - 1561
• Main Authors: Renton, Fiona J., Jeitner, Thomas M.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 14.06.1996; Elsevier Science
• Subjects: Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; cell cycle; Cell Cycle - drug effects; Cell Cycle - physiology; Cell Division - drug effects; Cell Division - physiology; Deferoxamine - pharmacology; desferrioxamine; DNA synthesis; General aspects; Glioma - drug therapy; Glioma - pathology; Humans; Iron Chelating Agents - pharmacology; iron chelators; Medical sciences; neural tumors; Neuroblastoma - drug therapy; Neuroblastoma - pathology; Pharmacology. Drug treatments; Tumor Cells, Cultured; iron chelators; DNA synthesis; neural tumors; desferrioxamine; cell cycle; Antineoplastic agent; Human; Nervous system diseases; Central nervous system; Cytotoxicity; Iron; Malignant tumor; In vitro; Glioma; Central nervous system disease; Cell cycle; Chelating agent; Mechanism of action; Tumor cell
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/0006-2952(96)00099-8

The current studies were designed to examine the conditions under which the ferric iron chelator desferrioxamine (DFO) arrested cell cycle progression and hence the proliferation of neural cell lines in vitro. DFO arrested proliferation at different stages of the cell cycle depending on the concentration and duration of drug exposure. Twenty-four-hour treatment with 160 μM DFO arrested glioma cells in G 1, whereas 72-hr treatment with 10 μM DFO acted to slow the passage of glioma cells through the cell cycle, eventually accumulating in G 2/M. Another iron chelator, ADR 529, also inhibited the proliferation of glioma cells by lengthening the period of the cycle and causing the cells to arrest in G 2/M. The effects of 10 and 160 μM DFO were irreversible after 24 and 48 hr, respectively, and 10 μM DFO became cytotoxic after 3 days. These observations demonstrate that DFO has different effects on the proliferation of neural tumor cell lines depending on the concentration and time of exposure, which result in different sites of cell cycle arrest. These different in vitro actions of DFO may have ramifications for the successful application of iron chelator therapy in vivo.